Adoptive transfer of autologous T cells followed by vaccination with MAGE-A4-derived peptides after chemotherapy for MAGE-A4-expressing advanced cancer patients
- Conditions
- Head and neck cancer, Ovarian cancer, Esophageal cancer, Multiple myeloma
- Registration Number
- JPRN-UMIN000001063
- Lead Sponsor
- Department of Immuno-gene Therapy, Mie University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Not provided
1)Positive either for HIV, HBV, HCV or HTLV-1 2)Allergic for agents used in this study, or prior allergic reactions requiring treatments 3)Notable fluid retention, including pleural effusion, ascites, or pericardial effusion. 4)Brain metastasis manifesting clinical signs and symptoms 5)Active infection 6)Unstable angina pectoris, history of myocardial infarction less than six months prior, or serious arrhythmia requiring treatments. 7)Interstitional pneumonia or pulmonary fibrosis 8)History of widespread bone marrow irradiation. 9)Paralysis or obstruction of gastrointestinal tracts. 10)Active double cancers occurring within five years, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable. 11)Uncontrolled diabetes mellitus 12)Women who are pregnant, milking , possibly pregnant, or refuse anticonception. 13)Judged as inappropriate for the study entry by the principle investigator or physicians responsible for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events
- Secondary Outcome Measures
Name Time Method Antigen-specific immune responses